News | July 22, 2014

AtriClip LAA Occulder System Surpasses 34,000 Units Sold

AtriClip is most widely used device indicated for left atrial appendage management

July 22, 2014 — AtriCure announced it has sold more than 34,000 AtriClip left atrial appendage (LAA) exclusion system devices worldwide.

The LAA is a muscular pouch attached to the heart’s left atrium. In patients with atrial fibrillation and other cardiac arrhythmias, blood can pool and form clots in the appendage, which may then leave the heart and cause strokes. One study concluded that more than 90 percent of detected blood clots in patients with atrial fibrillation are formed in the LAA.

For years, heart surgeons would remove the LAA with a cut-and-sew method during surgery, which required extra time on the heart-lung machine and posed a risk of hemorrhaging. In 2010, the AtriClip system was cleared for sale in the United States by the Food and Drug Administration (FDA) with the indication for occlusion of the LAA, under direct visualization, in conjunction with other open cardiac surgical procedures. The clearance was made after the EXCLUDE trial showed the LAA was closed successfully with the AtriClip device in 98.4 percent of patients, with no device-related mortality.

“The AtriClip device is quick to place and provides consistent occlusion of the appendage with minimal risk of hemorrhage," said J. Michael Smith, M.D., chief of cardiovascular surgery, director of robotics, co-director of transcatheter valve therapies and surgical research director of the Hatton Research Institute at TriHealth in Cincinnati.

In early 2014, AtriCure initiated the Stroke Feasibility study using the AtriClip system in a minimally invasive procedure on a beating heart. This study will evaluate the safely of the AtriClip when used for stroke prevention in patients with non-valvular atrial fibrillation who can’t take long-term anticoagulation medications. Complete exclusion of the LAA will be confirmed during the procedure using echo graphic imaging. The study will be conducted at seven hospitals in the United States, enrolling up to 30 patients.

“This study demonstrates our commitment to developing compelling solutions that improve patients’ lives and decrease the social and economic burden of atrial fibrillation,” said Mike Carrel, CEO of AtriCure. “The previous difficulty in obtaining complete appendage closure has largely been overcome with the use of the AtriClip system.”

For more information: www.atricure.com

Related Content

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders| March 29, 2017
March 29, 2017 — For patients with...
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
Dee Dee Wang, Henry Ford Hospital, 3D printing for cardiology, 3-D

Dr. Dee Dee Wang with part of Henry Ford Hospital's collection of 3-D printed hearts used for education and to preplan structural heart procedures.

Feature | 3-D Printing| March 03, 2017
March 3, 2017 — A Henry Ford Hospital study found a 100 percent success rate in left atrial appendage (LAA) occlusion
UAB, University of Alabama at Birmingham study, stroke prevention, non-valvular atrial fibrillation, NVAF
News | Atrial Fibrillation| October 25, 2016
A recent study from University of Alabama at Birmingham (UAB) researchers published in PLOS ONE compares different...
SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland
News | Left Atrial Appendage (LAA) Occluders| October 13, 2016
SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is...
CardioKinetix, Parachute device, Heart Failure device therapy

The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently. 

Feature | Heart Failure| September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the
Overlay Init